LONSURF will be launched in China for the treatment of metastatic colorectal cancer.

the !---- pharmaceutical company Taiho announced today that it will launch LONSURF (trifluorocane/dipyritin) in China for the treatment of metastatic colorectal cancer (mCRC), which was approved in China in August 2019.based on a study of TERRA III in patients with refractive mCRC in Asia (China, Korea and Thailand), LONSURF significantly extends the overall survival (OS) of mCRC patients.the drug is well tolerated and its toxicity is consistent with previously reported.TERRA study is a randomized, double-blind, placebo-controlled Phase III study that evaluated the efficacy and safety of oral LONSURF in patients with refractive mCRC.the study recruited 406 patients who had received at least two previous mCRC standard chemotherapy regimens and were resistant to these chemotherapy treatments.the study was conducted in China, South Korea and Thailand.patients were randomly assigned to BE treated with LONSURF or placebo.the main endpoint of the TERRA study was the improvement of OS relative to placebo.colorectal cancer is a cancer originating in the colon or rectal tract (part of the large intestine).may invade or transfer to other parts of the body due to abnormal cell growth.symptoms may include blood in feces, changes in bowel habits, weight loss, and tiredness..